64 results
Page 2 of 4
424B5
164xewmf
28 Mar 22
Prospectus supplement for primary offering
4:53pm
8-K
EX-1.1
drwxu69p du0fioq54
16 Jul 21
Entry into a Material Definitive Agreement
4:14pm
424B5
fhqs89q5f8580i7
16 Jul 21
Prospectus supplement for primary offering
4:07pm
8-K
EX-10.1
djw2ozcpr82jk9 je
13 Nov 20
Termination of a Material Definitive Agreement
4:02pm
8-K
EX-1.1
29jky37qhzlg5huvjyq9
26 Jun 20
Soleno Therapeutics Announces Pricing of $50 Million Public Offering of Common Stock
4:31pm
424B5
cmrs8c8g
25 Jun 20
Prospectus supplement for primary offering
4:01pm
424B5
2rmqt mcr5
23 Jun 20
Prospectus supplement for primary offering
4:06pm
8-K
EX-99.1
22266gj
6 Jan 20
Soleno Therapeutics Completes Target Enrollment in Ongoing DESTINY PWS Phase III Trial of DCCR in Prader Willi Syndrome
5:01pm
8-K
EX-1.1
i6kv1bl jqirauyy
25 Oct 19
Soleno Therapeutics Announces Pricing of $13.4 Million Public Offering of Common Stock
4:03pm
424B5
ifjfivh
25 Oct 19
Prospectus supplement for primary offering
12:00am
424B5
4ervx7pe8h
22 Oct 19
Prospectus supplement for primary offering
4:24pm
S-3
f0a58x mp
11 Jun 19
Shelf registration
5:05pm
424B3
ng2iu088ju dl18f
12 Apr 19
Prospectus supplement
4:41pm